구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Bimzelx (bimekizumab) | AIN457 (secukinumab) |
Overview Company | UCB | Novartis |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | IL-17A / IL-17F | Psoriatic Arthritis |
Overview Indication | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa | Asthma |
Overview Phase | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE |
Overview Content status | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. | — |
Positioning Known limitation | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. | — |
Positioning Development positioning | Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents. | — |
MoA Mechanism | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | PASI/IGA response, hs-CRP in axial disease. | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | ~23 days | 31 h |
PK/PD Species | Cynomolgus monkey, PASI 90/100, HiSCR in HS, ASAS40 in axSpA | Rat, Human |
PK/PD Animal (cat.) | Human, NHP, In vitro | Human, Rat |
PK/PD Experiment | pd | PD |
Toxicology Species | Cynomolgus monkey | Rat, Human |
Toxicology Animal (cat.) | — | Human, Rat |
Toxicology Major finding | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Toxicology CRS | N/A | — |
Clinical Safety signal | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Clinical Selected reported efficacy | — | 9% |
Clinical PASI75 | PASI 100 than secukinumab at week 16 and mai | — |
Clinical Result source | BE RADIANT (NCT03536884) / BE VIVID / BE SURE | ClinicalTrials.gov NCT03131570 |
Clinical Program phase | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03536884 | NCT03131570 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Bimzelx (bimekizumab) | AIN457 (secukinumab) |
Overview Company | UCB | Novartis |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | IL-17A / IL-17F | Psoriatic Arthritis |
Overview Indication | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa | Asthma |
Overview Phase | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE |
Overview Content status | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. | — |
Positioning Known limitation | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. | — |
Positioning Development positioning | Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents. | — |
MoA Mechanism | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | PASI/IGA response, hs-CRP in axial disease. | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | ~23 days | 31 h |
PK/PD Species | Cynomolgus monkey, PASI 90/100, HiSCR in HS, ASAS40 in axSpA | Rat, Human |
PK/PD Animal (cat.) | Human, NHP, In vitro | Human, Rat |
PK/PD Experiment | pd | PD |
Toxicology Species | Cynomolgus monkey | Rat, Human |
Toxicology Animal (cat.) | — | Human, Rat |
Toxicology Major finding | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Toxicology CRS | N/A | — |
Clinical Safety signal | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Clinical Selected reported efficacy | — | 9% |
Clinical PASI75 | PASI 100 than secukinumab at week 16 and mai | — |
Clinical Result source | BE RADIANT (NCT03536884) / BE VIVID / BE SURE | ClinicalTrials.gov NCT03131570 |
Clinical Program phase | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03536884 | NCT03131570 |
추천 비교
추천 비교